Perrigo Company plc (NYSE:PRGO) Given Consensus Recommendation of “Reduce” by Analysts

Perrigo Company plc (NYSE:PRGO) has been given a consensus recommendation of “Reduce” by the six ratings firms that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.3333.

PRGO has been the topic of a number of analyst reports. Zacks Research cut Perrigo from a “hold” rating to a “strong sell” rating in a research report on Friday, March 20th. JPMorgan Chase & Co. dropped their target price on Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Canaccord Genuity Group cut their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a report on Thursday, February 26th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd.

Perrigo Stock Up 1.8%

PRGO stock traded up $0.17 during midday trading on Friday, hitting $9.55. The stock had a trading volume of 549,896 shares, compared to its average volume of 3,134,897. The business has a 50-day moving average of $12.85 and a two-hundred day moving average of $15.74. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -0.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.41. Perrigo has a 52-week low of $9.23 and a 52-week high of $28.43.

Perrigo (NYSE:PRGO) last released its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). Perrigo had a positive return on equity of 9.41% and a negative net margin of 33.51%.The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the company earned $0.93 earnings per share. The firm’s quarterly revenue was down 2.5% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. As a group, equities research analysts forecast that Perrigo will post 2.56 earnings per share for the current fiscal year.

Perrigo Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 24th. Stockholders of record on Monday, March 2nd were issued a dividend of $0.29 per share. The ex-dividend date was Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 12.2%. Perrigo’s dividend payout ratio is presently -11.28%.

Hedge Funds Weigh In On Perrigo

A number of hedge funds have recently added to or reduced their stakes in the company. Amundi boosted its stake in Perrigo by 11.7% during the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after purchasing an additional 556 shares during the last quarter. Slocum Gordon & Co LLP lifted its holdings in shares of Perrigo by 1.1% during the third quarter. Slocum Gordon & Co LLP now owns 53,253 shares of the company’s stock valued at $1,186,000 after purchasing an additional 602 shares in the last quarter. Kestra Investment Management LLC boosted its position in shares of Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after buying an additional 642 shares during the last quarter. State of Wyoming boosted its position in shares of Perrigo by 7.8% during the third quarter. State of Wyoming now owns 8,988 shares of the company’s stock valued at $200,000 after buying an additional 653 shares during the last quarter. Finally, First Citizens Bank & Trust Co. increased its holdings in Perrigo by 4.7% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 17,323 shares of the company’s stock worth $386,000 after buying an additional 775 shares in the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.